A mixed‐methods study of cyclin‐dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers

BACKGROUND: Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients’ health‐related quality of life (HRQOL) and treatment outcomes...

Descripción completa

Detalles Bibliográficos
Autores principales: Oswald, Laura B., Arredondo, Brandy, Kadono, Mika, Martinez‐Tyson, Dinorah, Meade, Cathy D., Penedo, Frank, Antoni, Michael H., Soliman, Hatem, Costa, Ricardo L. B., Jim, Heather S. L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290228/
https://www.ncbi.nlm.nih.gov/pubmed/34165265
http://dx.doi.org/10.1002/cam4.4055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8290228/
https://www.ncbi.nlm.nih.gov/pubmed/34165265
http://dx.doi.org/10.1002/cam4.4055

Ejemplares similares